A new bioinformatics approach for prediction of potential tumor neoantigens based on the cancer genome atlas dataset.
- Author:
Chuanxi HUANG
1
;
Jie MA
2
;
Chen WU
1
;
Yunping ZHU
2
Author Information
- Publication Type:Journal Article
- Keywords: gene mutation; immunotherapy; the cancer genome atlas (TCGA); tumor neoantigen
- MeSH: Antigens, Neoplasm; Computational Biology; Genome, Human; Humans; Immunotherapy; Mutation; Neoplasms
- From: Chinese Journal of Biotechnology 2019;35(7):1295-1306
- CountryChina
- Language:Chinese
- Abstract: Tumor-specific gene mutations might generate suitable neoepitopes for cancer immunotherapy that are highly immunogenic and absent in normal tissues. The high heterogeneity of the tumor genome poses a big challenge for precision cancer immunotherapy. Mutations characteristic of each tumor can help to distinguish it from other tumors. Based on these mutations' characteristic, it is possible to develop immunotherapeutic strategies for specific tumors. In this study, a tumor neoantigen prediction scheme was proposed, in which both the intracellular antigen presentation process and the ability to bind with extracellular MHC molecule were taken into consideration. The overall design is meritorious and may help reduce the cost for validation experiments compared with conventional methods. This strategy was tested with several cancer genome datasets in the TCGA database, and a number of potential tumor neoantigens were predicted for each dataset. These predicted neoantigens showed tumor type specificity and were found in 20% to 70% of cancer patients. This scheme might prove useful clinically in future.
